These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19538527)

  • 1. Midkine in plasma as a novel breast cancer marker.
    Ibusuki M; Fujimori H; Yamamoto Y; Ota K; Ueda M; Shinriki S; Taketomi M; Sakuma S; Shinohara M; Iwase H; Ando Y
    Cancer Sci; 2009 Sep; 100(9):1735-9. PubMed ID: 19538527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma.
    Alper O; Stetler-Stevenson WG; Harris LN; Leitner WW; Ozdemirli M; Hartmann D; Raffeld M; Abu-Asab M; Byers S; Zhuang Z; Oldfield EH; Tong Y; Bergmann-Leitner E; Criss WE; Nagasaki K; Mok SC; Cramer DW; Karaveli FS; Goldbach-Mansky R; Leo P; Stromberg K; Weil RJ
    Cancer Sci; 2009 Sep; 100(9):1748-56. PubMed ID: 19594548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].
    Ruibal A; Garrido Pumar M; Arias JI
    Rev Esp Med Nucl; 2006; 25(3):180-3. PubMed ID: 16762272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.
    Wu SG; He ZY; Zhou J; Sun JY; Li FY; Lin Q; Guo L; Lin HX
    Breast; 2014 Feb; 23(1):88-93. PubMed ID: 24291374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.
    Elfagieh M; Abdalla F; Gliwan A; Boder J; Nichols W; Buhmeida A
    Tumour Biol; 2012 Dec; 33(6):2371-7. PubMed ID: 22948780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ.
    Takada K; Kashiwagi S; Asano Y; Goto W; Morisaki T; Takahashi K; Fujita H; Takashima T; Tomita S; Hirakawa K; Ohira M
    BMC Cancer; 2020 Jun; 20(1):513. PubMed ID: 32493410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
    Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
    Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
    Park BJ; Cha MK; Kim IH
    BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARĪ²2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
    Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
    Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
    Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of tumor markers in southern Indian breast cancer patients.
    Porika M; Malotu N; Veldandi UK; Yadala N; Abbagani S
    Asian Pac J Cancer Prev; 2010; 11(1):157-9. PubMed ID: 20593949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer.
    Moazzezy N; Farahany TZ; Oloomi M; Bouzari S
    Asian Pac J Cancer Prev; 2014; 15(4):1685-8. PubMed ID: 24641390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.